Skip to main content

Anti-IL-1 β Therapies

Buy Article:

$113.00 plus tax (Refund Policy)

IL-1β is one of the major cytokines implicated in the pathogenesis of many inflammatory-associated diseases. Recent studies demonstrate that IL-1 β is activated through inflammasomes, which are formed upon recognition of danger signals by the immune system. IL-1 β is, therefore, becoming a focus for the development of new anti-inflammatory drug products. Current issued patents mainly covered the methods and the use of four types of IL-1 β blockade compounds, namely anti-IL-1 β antibody, IL-1 receptor antagonists such as sIL-1Ra and icIL-1Ra and IL1 trap. Two agents, Rilonacept and canakinumab were approved by the US FDA and others are in trial, in which beneficial results have been reported. One can expect that upcoming patents in the field of inflammasome research will facilitate the development of new therapeutic interventions.

No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Keywords: Card8/NDPP1/Tucan/CARDINAL; IL-1 blockade compounds; IL-1 Signaling; IL-1 receptor antagonists; IL-1 trap; IL-1 β; Innate Immune Defense; NALP1 and NALP3; NLR pathways; Systemic-Onset Juvenile Idiopathic Arthritis; antibody; cytokine precursors; icIL-1Ra; inflammasome; inflammatory disease; pathogenesis; sIL-1Ra

Document Type: Research Article

Publication date: 2011-08-01

More about this publication?
  • Recent Patents on DNA and Gene Sequences publishes review articles by experts on recent patents on DNA and gene sequences. A selection of important and recent patents in the field is also included in the journal. The journal is essential reading for all researchers involved in applied molecular biology.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more